Track Immunic, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Immunic, Inc. IMUX · Stock Open Immunic, Inc. in new tab

7.52 USD
EPS
-3.83
P/B
-13.57
ROE
-138.17
Beta
1.48
Target Price
42.64 USD
Loading chart...
Key Metrics
Earnings dateFeb. 25, 2027
EPS-3.83
Book Value-0.55
Price to Book-13.57
Debt/Equity0.44
% Insiders2.182%
Estimates
Forward P/E-3.14
Forward EPS-2.39
Target Mean Price42.64

DCF valuation

Model fair value for Immunic, Inc. (IMUX)
Result
Sign in to run the valuation for IMUX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
11 analysts · consensus Strong buy · mean target 42.64 USD (low 20.00, high 85.00) · as of 16 Nov 2026
Low 20.00
Mean 42.64
High 85.00
Price 7.52
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Immunic, Inc. Logo Immunic, Inc. Analysis (IMUX)

United States Health Care Official Website Stock

Is Immunic, Inc. a good investment? Immunic, Inc. (IMUX) is currently trading at 7.52 USD. Market analysts have a consensus price target of 42.64 USD. This suggests a potential upside from current levels.

Earnings Schedule: Immunic, Inc. is expected to release its next earnings report on Feb. 25, 2027. The market consensus estimate for Forward EPS is -2.39.

Investor FAQ

Does Immunic, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Immunic, Inc.?

Immunic, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Feb. 25, 2027. The company currently has a trailing EPS of -3.83.

Company Profile

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

Exchange Ticker
NMS (United States) IMUX
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
April 15, 2019 1:40
April 27, 2026 1:10
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion